Connect with us

News

The American Association of Bank Directors welcomes Treliant LLC as a Sponsor and Supporter of AABD’s Bank General Counsel Committee

gbafNews28

The American Association of Bank Directors (AABD) today announced that Treliant LLC (Treliant) has become a sponsor.

“Bank General Counsel can play a crucial role in advising their bank board of directors on how to navigate through challenging times. Treliant has offered its support for AABD’s efforts to lend a hand to bank General Counsel to help make bank board members more effective and less susceptible to risk of personal liability,” David Baris, AABD’s president said.

Treliant is a premier bank consulting firm with offices in Washington DC and New York City, providing comprehensive support for corporate and regulatory compliance programs, risk management, global financial crimes compliance, corporate and regulatory investigations, and business performance. It has consulted with a range of banks, from small community banks to large, international financial institutions, on a variety of matters.

Two of Treliant’s recent engagements include:

  • Conducting an assessment of a top 10 U.S. financial institution’s complaint management system to review its baseline state and perform a gap analysis between the system and CFPB recommendations, resulting in steps to strengthen the system
  • Serving as independent consultant to the Federal Reserve for a financial crimes compliance related enforcement action against a large complex international bank

“It is essential that bank boards and general counsel work closely together to meet current challenges,” Baris said. “A robust corporate governance framework and strong corporate culture is essential. General Counsel can play a key role. AABD’s periodic conference calls and communications with members of its General Counsel Committee to share ideas and recent developments assist counsel to successfully work with their boards and senior management.”

“I am delighted that Treliant has become a sponsor of AABD,” Scott Fisher, Treliant CEO, said. “It is the only trade association in the United States that consistently speaks out for the interests of bank directors. It provides invaluable support for bank boards to perform their responsibilities effectively and assists bank General Counsels in that endeavor.”

About AABD

Founded in 1989, the non-profit American Association of Bank Directors is the only trade group in the United States solely devoted to bank directors and their information, education, and advocacy needs. The Institute for Bank Director Education was established in 1993 as the educational arm of AABD. Its purpose is to act as a clearinghouse for education programs designed for bank and savings institution directors that support the nationally recognized AABD Director Certification Program and to offer a six-hour core course to all bank directors. AABD has published, among other publications, the Bank Director Regulatory Burden Report, the first public compilation of over 800 laws, regulations, and federal banking agency guidance that impose various requirements on bank directors and their boards and board committee; FDIC Director Suits: Lessons Learned, a guide for bank directors to be prepared for future recessions; Bank Director Standards of Care and Protection: A Fifty-State Survey; and the Practical Handbook on Fair Lending for Bank Directors and Executive Officers, designed to provide straightforward advice on how bank boards can achieve effective oversight over fair lending risk and engage in best practices.

About Treliant

Treliant is a multi-industry consulting firm that serves organizations around the globe. Our firm serves financial institutions, consumer-oriented businesses, other corporations, and law firms. As a firm of leading professionals from industry and government, we assist our clients in navigating regulatory requirements and on best practices, while meeting strategic and operational objectives. We partner with clients as trusted advisors and via managed services including through secondments, interim resources, and other outsourcing strategies. Our advisory and assurance services and specialized, high quality business solutions strengthen our clients’ corporate and regulatory compliance programs, risk management, and business performance. We also provide comprehensive support for corporate and regulatory investigations, litigation, and as government agency monitors and independent consultants. We serve companies from Main Street to Wall Street and across the globe. For more information, visit www.Treliant.com.

DAVID BARIS

(301) 938-1887

[email protected]

MELISSA PAZORNIK

(202) 875-4741

[email protected]

News

Arcturus Therapeutics to Present at Upcoming Investor Conference

gbafNews28

Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will be presenting at Piper Sandlers 32nd Annual Virtual Healthcare Conference:

The Road Ahead for COVID-19 Vaccines: What We Know and Questions Still to be Answered into 2021

Panel Presentation Date: Tuesday, Dec 1, 2020 Time: 10:00 a.m. ET

About Arcturus Therapeutics

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR lipid-mediated delivery, (ii) STARR„¢ mRNA Technology and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus diverse pipeline of RNA therapeutic and vaccine candidates includes self-replicating mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to potentially treat Ornithine Transcarbamylase (OTC) Deficiency, Cystic Fibrosis, and Cardiovascular Disease along with partnered programs including Glycogen Storage Disease Type 3, Hepatitis B Virus, and non-alcoholic steatohepatitis (NASH). Arcturus versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics. Arcturus technologies are covered by its extensive patent portfolio (200 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries). Arcturus commitment to the development of novel RNA therapeutics has led to collaborations with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, CureVac AG, Synthetic Genomics Inc., Duke-NUS, and the Cystic Fibrosis Foundation. For more information visit www.ArcturusRx.com. In addition, please connect with us on Twitter and LinkedIn.

IR and Media Contacts

Arcturus Therapeutics

Neda Safarzadeh

(858) 900-2682

[email protected]

Kendall Investor Relations

Carlo Tanzi, Ph.D.

(617) 914-0008

[email protected]

Continue Reading

News

Diamond S Shipping Inc. Comments on an Incident Involving One of Its Vessels

gbafNews28

Diamond S Shipping Inc. (NYSE: DSSI) (Diamond S or the Company) announced the receipt of an incident report involving a kidnapping on one of its product tanker vessels, the Agisilaos, as it was approaching the port of Lome, Togo on November 29, 2020.  The vessel is managed and crewed by Capital Ship Management Corp. (˜Capital) who informed Diamond S about the kidnapping of four crew members. The Company confirms that there were 22 seafarers aboard when the attack occurred.  There have been no reports of injuries at this time. All appropriate authorities have been notified and Diamond S is fully supporting Capital as they respond to this situation. Diamond S will not comment further on these operational issues to avoid potentially jeopardizing the safety of the crew members being held or prolonging their stay in captivity.

About Diamond S Shipping Inc.

Diamond S Shipping Inc. (NYSE Ticker: DSSI) owns and operates 66 vessels on the water, including 15 Suezmax vessels, one Aframax and 50 medium-range (MR) product tankers. Diamond S Shipping is one of the largest energy shipping companies providing seaborne transportation of crude oil and refined petroleum products in the international shipping markets.  The Company is headquartered in Greenwich, CT.  More information about the Company can be found at www.diamondsshipping.com.

Investor Relations Inquiries:

Robert Brinberg

Tel: +1-212-517-0810

E-mail: [email protected]

Continue Reading

News

Takeda Completes Sale of Select OTC and Non-Core Assets to Celltrion in Asia Pacific

gbafNews28

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (Takeda) today announced the completion of its previously-announced sale of a portfolio of select products to Celltrion Inc. (Celltrion) for a total value of $278 million USD inclusive of milestone payments. The portfolio includes 18 pharmaceutical products and over-the-counter (OTC) products sold in Asia Pacific, which is part of Takedas Growth & Emerging Markets Business Unit. This divestment agreement was first announced in June 2020.

The divested portfolio includes pharmaceutical products and OTC products in the Cardiovascular, Diabetes and General Medicine therapeutic areas, sold in Australia, Hong Kong, Macau, Malaysia, Philippines, Singapore, South Korea, Taiwan and Thailand. The products, while addressing key patient needs in these countries and territories, are outside of the business areas Takeda has chosen as core to its global long-term growth. As part of the deal, Takeda will continue to manufacture the portfolio of divested products and supply them to Celltrion under a manufacturing and supply agreement.

Takeda intends to use the proceeds from the sale to reduce its debt and accelerate deleveraging towards its target of 2x net debt/adjusted EBITDA within Fiscal Years 2021“2023.

Takeda has exceeded its $10 billion non-core asset divestiture target and has announced 10 deals since January 2019 to date for a total aggregate value of up to ~$11.3 billion, including agreements to divest:

  • Takeda Consumer Healthcare Company Limited to Oscar A-Co KK, a company controlled by funds managed by The Blackstone Group Inc. and its affiliates for a¯total value of approximately JPY 242.0 billion ($2.3 billion USD).
  • Other non-core portfolio assets within the Growth & Emerging Markets Business Unit, totaling ~$1.7 billion* with three separate buyers.
  • Select OTC and non-core assets in Europe to Orifarm for approximately $670 million.
  • Non-core assets in Europe and Canada to Cheplapharm for approximately $562 million.
  • The TachoSil Fibrin Sealant Patch to Corza Health, Inc. for approximately ‚¬350 million.

Transactions still pending are expected to close by March 31, 2021, subject to customary legal and regulatory closing conditions.

* Including an agreement for $825 million with Hypera S.A. for select non-core products in Latin America which remains subject to close.

About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Diseases, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries.

For more information, visit https://www.takeda.com.

Important Notice

For the purposes of this notice, press release means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (Takeda) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, Takeda is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words we, us and our are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takedas future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as targets, plans, believes, hopes, continues, expects, aims, intends, ensures, will, may, should, would, could anticipates, estimates, projects or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takedas global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations; the success of or failure of product development programs; decisions of regulatory authorities and the timing thereof; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takedas operations and the timing of any such divestment(s); and other factors identified in Takedas most recent Annual Report on Form 20-F and Takedas other reports filed with the U.S. Securities and Exchange Commission, available on Takedas website at: https://www.takeda.com/investors/reports/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takedas future results.

Japanese Media

Kazumi Kobayashi

[email protected]

+81 (0) 3-3278-2095

Media outside Japan

Justine Grosvenor

[email protected]

+1 872 226 6701

Investor Relations Contact:

Christopher O’Reilly

[email protected]

+81 (0) 3-3278-2306

Continue Reading
Editorial & Advertiser disclosureOur website provides you with information, news, press releases, Opinion and advertorials on various financial products and services. This is not to be considered as financial advice and should be considered only for information purposes. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third party websites, affiliate sales networks, and may link to our advertising partners websites. Though we are tied up with various advertising and affiliate networks, this does not affect our analysis or opinion. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you, or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish sponsored articles or links, you may consider all articles or links hosted on our site as a partner endorsed link.
gbafNews28 gbafNews28
News54 mins ago

Celltrion Completes Acquisition of Primary Care (PC) Product Assets for Asia Pacific Markets from Takeda Pharmaceutical Company Limited

Celltrion (KRX:068270) has completed the acquisition of select primary care assets from Takeda Pharmaceutical Company Limited (Takeda) in Asia Pacific,...

gbafNews28 gbafNews28
News54 mins ago

Takeda Completes Sale of Select OTC and Non-Core Assets to Celltrion in Asia Pacific

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (Takeda) today announced the completion of its previously-announced sale of a portfolio of select products...

gbafNews28 gbafNews28
News54 mins ago

Diamond S Shipping Inc. Comments on an Incident Involving One of Its Vessels

Diamond S Shipping Inc. (NYSE: DSSI) (Diamond S or the Company) announced the receipt of an incident report involving a...

gbafNews28 gbafNews28
News54 mins ago

Arcturus Therapeutics to Present at Upcoming Investor Conference

Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development...

gbafNews28 gbafNews28
News56 mins ago

KBRA Assigns Ratings to Sunnova Sol II Issuer, LLC, Series 2020-2

Kroll Bond Rating Agency (KBRA) assigns ratings to two note classes issued by Sunnova Sol II Issuer, LLC, Series 2020-2....

gbafNews28 gbafNews28
News1 hour ago

Laura J. Schumacher Joins CrowdStrike’s Board of Directors

CrowdStrike Holdings, Inc. (Nasdaq: CRWD), a leader in cloud-delivered endpoint and workload protection, today announced the appointment of Laura J....

gbafNews28 gbafNews28
News1 hour ago

Cornerstone Community Bancorp Announces Stock Repurchase Plan

Cornerstone Community Bancorp, (OTC Pink: CRSB), the parent company of Cornerstone Community Bank, announced today that its Board of Directors...

gbafNews28 gbafNews28
News1 hour ago

VIQ Solutions Reports Third Quarter Results

VIQ Solutions Inc. (“VIQ” or the “Company”) (TSX Venture Exchange: VQS and OTC Markets: VQSLF) a global provider of secure,...

gbafNews28 gbafNews28
News1 hour ago

Spectra7 Announces Third Quarter Financial Results

(TSX-V:SEV) Spectra7 Microsystems Inc. (Spectra7 or the Company), a leading provider of high-performance analog semiconductor products for broadband connectivity markets,...

gbafNews28 gbafNews28
News1 hour ago

Oshkosh Corporation to Present at the Credit Suisse 8th Annual Virtual Industrials Conference

Oshkosh Corporation (NYSE:OSK), a leading innovator of mission-critical vehicles and essential equipment, announced today that it will present at the...